Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Nanotechnology-enabled deep profiling of the blood and brain proteome at the intersection of neurodegeneration and neurooncology

Project description

Biomarker identification for neurodegenerative diseases and brain tumours

Diagnostic biomarkers are crucial for early disease detection and effective management, providing essential information about disease presence, progression and response to treatment. In Alzheimer's disease (AD) and glioblastoma (GBM), there is a significant gap in available biomarkers, making early diagnosis and monitoring challenging. The ERC-funded NanoNeuroOmics project proposes to use nanoparticles to isolate and identify brain disease-specific protein markers from blood. Researchers will profile blood and brain proteomes to uncover early diagnostic biomarkers and explore the molecular links between AD and GBM, focusing on their inverse comorbidity. The identification of overlapping pathways will improve understanding of disease biology and advance personalised treatment and management.

Objective

NanoNeuroOmics ambition is to bring together nanotechnology, proteomics and blood biomarker discovery at the emerging intersection of neurodegeneration and neurooncology. NanoNeuroOmics proposes a nanotechnology-based innovative solution for the integrative profiling of the blood and brain tissue proteomes to address two interconnected challenges: i) The unmet clinical need for early diagnostic and disease-monitoring blood biomarkers for two of the most challenging Central Nervous System disorders, namely Alzheimer’s disease (AD) and Glioblastoma (GBM); and ii) The AD-GBM ‘inverse comorbidity’ knowledge gap and intriguing molecular interrelation. NanoNeuroOmics presents a novel approach, in which nanoparticles are employed as scavenging agents to uncover brain disease-specific protein markers in blood, otherwise buried under the overwhelming signal of highly abundant molecules. NanoNeuroOmics aims to tackle the technological challenge of discovering highly specific blood biomarkers, by longitudinally tracking blood and brain proteomic signals at different stages of disease progression. To leverage its full potential, the proposed research programme combines longitudinal preclinical studies with human patient clinical validation studies. Such multi-dimensional proteomic approaches are expected to pioneer new blood biomarker discoveries and to provide mechanistic insight into the comorbidity of neurological diseases. NanoNeuroOmics attempts to discover a distinct set of dysregulated proteins for each of AD and GBM independently and to unveil overlapping molecular pathways to explain the AD-GBM inverse comorbidity. In a broader context, NanoNeuroOmics aspires to bridge the gap between brain pathophysiology and molecular alterations in the blood, across the biological continuum of disease progression. The project takes on a multidisciplinary approach and builds on breakthroughs in nanotechnology and omics sciences, to advance early detection and stratified medicine.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

THE UNIVERSITY OF MANCHESTER
Net EU contribution
€ 1 494 954,00
Address
OXFORD ROAD
M13 9PL Manchester
United Kingdom
Region
North West (England) Greater Manchester Manchester
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 494 954,00

Beneficiaries (1)